Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
AMITID vs AMRIX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.
Major depressive disorder,Neuropathic pain,Fibromyalgia,Migraine prophylaxis,Chronic tension-type headache,Irritable bowel syndrome,Enuresis
Treatment of spasticity due to multiple sclerosis, spinal cord injury, or other spinal cord disorders
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal elimination half-life approximately 32 hours (range 28–40 hours); clinically relevant for once-daily dosing in chronic muscle spasm
Hepatic via CYP2D6, CYP2C19, CYP3A4; active metabolite nortriptyline.
Hepatic via deamination; primarily metabolized by monoamine oxidase B (MAO-B) to inactive metabolites.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal: approximately 40% as unchanged drug and metabolites; biliary/fecal: minimal; total clearance: 2.5 L/min
90-95% bound primarily to albumin and α1-acid glycoprotein.
40–45% bound to serum proteins, primarily albumin
3-5 L/kg; indicates extensive tissue distribution.
5–8 L/kg; suggests extensive tissue distribution, including skeletal muscle
Oral: 60-70%; Intravenous: 100%.
Oral: 85–95% (extended-release formulation)
GFR ≥30 m L/min: no adjustment. GFR 15–29 m L/min: reduce dose by 50%. GFR <15 m L/min: contraindicated or use with extreme caution, maximum 25 mg/day.
No specific dose adjustment recommended; use with caution in severe renal impairment (Cr Cl < 30 m L/min).
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: avoid use.
Contraindicated in Child-Pugh class C. For Child-Pugh class A or B: initiate at 15 mg once daily; do not increase dose. Use with caution.
Not FDA-approved for use in children <12 years. For adolescent depression (off-label): start 25 mg/day, titrate up to 50–100 mg/day. Weight-based: 1–3 mg/kg/day, not to exceed 150 mg/day.
Safety and efficacy not established in pediatric patients under 12 years. For ages 12 and older, same as adult dosing.
Start at 10–25 mg orally at bedtime; increase by 10–25 mg every 3–7 days to effective dose, typically 50–75 mg/day. Maximum 100 mg/day due to increased risk of anticholinergic effects, sedation, and orthostatic hypotension.
Initiate at 15 mg once daily. Due to higher incidence of anticholinergic effects and falls, monitor closely; consider lower doses in frail elderly.
Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults with major depressive disorder and other psychiatric disorders.
None
Clinical worsening and suicide risk,Serotonin syndrome,Cardiovascular effects (QT prolongation, arrhythmia),Anticholinergic effects,Seizures,Angle-closure glaucoma,Urinary retention,Hepatic impairment,Hyponatremia
Abrupt discontinuation may precipitate withdrawal syndrome including hallucinations, seizures, autonomic instability.,May cause sedation, dizziness, and muscle weakness; caution with activities requiring alertness.,Use with caution in patients with impaired renal function due to reduced clearance.,May exacerbate seizures in patients with epilepsy.,Avoid concomitant use with other CNS depressants.
Hypersensitivity to amitriptyline,Concomitant use with MAOIs (within 14 days),Acute recovery phase after myocardial infarction,Concurrent use of cisapride or other QT-prolonging drugs
Hypersensitivity to amrix or baclofen.,Abrupt withdrawal is contraindicated; must be tapered.,Concomitant use with MAO inhibitors is contraindicated due to risk of hypertensive crisis.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Tyramine-rich foods (aged cheese, cured meats, fermented products) should be limited due to risk of hypertensive crisis. Maintain adequate fluid intake to prevent constipation.
Avoid grapefruit and grapefruit juice during treatment as they may increase cyclobenzaprine levels. Taking AMRIX with or without food does not significantly affect absorption. Alcohol should be strictly avoided as it potentiates CNS depression.
First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, based on observational studies. Absolute risk is low. Second and third trimesters: Chronic use may lead to neonatal adaptation syndrome (irritability, respiratory distress) and anticholinergic effects (e.g., constipation, urinary retention). Late third trimester exposure may increase risk of persistent pulmonary hypertension of the newborn (PPHN).
Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacking. Use only if clearly needed. First trimester: no specific teratogenic effects documented; second and third trimesters: avoid near term due to potential neonatal effects (e.g., sedation, withdrawal).
Amitriptyline and its active metabolite nortriptyline are excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.5–1.5. Relative infant dose is low (estimated <2% of weight-adjusted maternal dose). No adverse effects reported in infants followed prospectively. The American Academy of Pediatrics considers amitriptyline compatible with breastfeeding. However, monitor infant for sedation, poor feeding, and growth.
Cyclobenzaprine is excreted into human milk in small amounts. M/P ratio: not established. Use with caution in nursing mothers; monitor infant for sedation, poor feeding, or hypotonia.
Pharmacokinetic changes in pregnancy (increased volume of distribution, hepatic metabolism, renal clearance) may reduce serum drug concentrations. Therapeutic drug monitoring (if available) can guide dose adjustments; clinical response may require dose increases by 30–50% in the second and third trimesters. Avoid abrupt withdrawal; taper if discontinuing.
No specific dose adjustments are recommended based on pharmacokinetic changes in pregnancy; however, due to potential for increased clearance, lowest effective dose should be used. Avoid use during labor and delivery due to potential neonatal depression.
Amitriptyline is a tricyclic antidepressant with strong anticholinergic effects; monitor for QT prolongation, especially in elderly or those with cardiac disease. Start low (10-25 mg at bedtime) and titrate slowly. Avoid in recent MI, narrow-angle glaucoma, and urinary retention. Use with caution in seizure disorders.
AMRIX (cyclobenzaprine extended-release) should not be used longer than 2-3 weeks due to lack of evidence for efficacy in muscle spasm beyond that period. It has significant anticholinergic effects; avoid in patients with glaucoma, urinary retention, or those taking MAOIs. Do not crush or chew capsules; administer once daily at same time. Onset of action is delayed compared to immediate-release cyclobenzaprine.
Take this medication at bedtime as it may cause drowsiness.,Avoid alcohol and other CNS depressants.,Do not stop abruptly; taper under medical supervision to avoid withdrawal symptoms.,May cause dry mouth, constipation, blurred vision; report severe side effects like fainting or irregular heartbeat.,Full therapeutic effect may take 2-4 weeks.
Take AMRIX exactly once daily at the same time each day; do not crush, chew, or open the capsule.,Avoid alcohol and other CNS depressants (e.g., benzodiazepines, opioids) as they increase the risk of severe drowsiness and dizziness.,Do not drive or operate heavy machinery until you know how AMRIX affects you; it may cause drowsiness, dizziness, or blurred vision.,Contact your healthcare provider if you experience symptoms of serotonin syndrome (e.g., agitation, hallucinations, rapid heart rate, fever, muscle stiffness, nausea, diarrhea).,Do not use AMRIX for longer than 2-3 weeks unless specifically directed by your doctor; prolonged use is not recommended.,Inform your doctor if you have a history of urinary retention, glaucoma, thyroid disorders, heart problems, or liver disease.,If you miss a dose, take it as soon as you remember unless it is almost time for your next dose; do not double the dose.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about AMITID vs AMRIX, answered by our medical review team.
AMITID is a Tricyclic Antidepressant that works by Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.. AMRIX is a Muscle Relaxant that works by Centrally acting muscle relaxant; it is the R-enantiomer of baclofen. Agonist at GABA-B receptors in the spinal cord, leading to inhibition of monosynaptic and polysynaptic spinal reflexes, thereby reducing muscle spasticity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between AMITID and AMRIX depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of AMITID is: 75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.. The standard adult dose of AMRIX is: 15 mg orally once daily. May increase to 30 mg once daily if needed, after at least 1 week. Maximum 30 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between AMITID and AMRIX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. AMITID is classified as Category C. First trimester: Amitriptyline (likely the active ingredient in AMITID) is associated with a small increased risk of congenital malformations, particularly cardiovascular defects, . AMRIX is classified as Category C. Cyclobenzaprine (AMRIX) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated fetal risk, but adequate well-controlled studies in pregnant women are lacki. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.